REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of REGENXBIO Inc. (NASDAQ:RGNX) have received an average recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $30.00.

Several equities analysts recently commented on RGNX shares. Chardan Capital reiterated a “buy” rating and issued a $52.00 target price on shares of REGENXBIO in a research note on Thursday, November 20th. Leerink Partners upped their price objective on shares of REGENXBIO from $16.00 to $20.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. Stifel Nicolaus raised their target price on shares of REGENXBIO from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. HC Wainwright restated a “buy” rating and issued a $34.00 target price on shares of REGENXBIO in a report on Tuesday, October 7th. Finally, Royal Bank Of Canada increased their price target on shares of REGENXBIO from $17.00 to $19.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RGNX. AQR Capital Management LLC increased its stake in REGENXBIO by 2,247.7% during the first quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company’s stock worth $4,437,000 after acquiring an additional 594,161 shares during the last quarter. Jane Street Group LLC grew its holdings in shares of REGENXBIO by 151.1% during the 1st quarter. Jane Street Group LLC now owns 414,067 shares of the biotechnology company’s stock worth $2,961,000 after purchasing an additional 249,156 shares during the period. Acadian Asset Management LLC acquired a new stake in REGENXBIO during the 1st quarter worth approximately $1,123,000. Pallas Capital Advisors LLC raised its holdings in REGENXBIO by 67.1% in the second quarter. Pallas Capital Advisors LLC now owns 17,407 shares of the biotechnology company’s stock valued at $143,000 after buying an additional 6,992 shares during the period. Finally, Wealth Enhancement Advisory Services LLC lifted its position in REGENXBIO by 78.4% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 30,630 shares of the biotechnology company’s stock valued at $268,000 after buying an additional 13,458 shares in the last quarter. Institutional investors and hedge funds own 88.08% of the company’s stock.

REGENXBIO Stock Performance

Shares of NASDAQ RGNX opened at $14.10 on Friday. The firm has a market cap of $713.74 million, a P/E ratio of -4.06 and a beta of 1.07. REGENXBIO has a 1 year low of $5.03 and a 1 year high of $15.84. The firm’s 50 day moving average price is $13.42 and its 200 day moving average price is $11.10.

REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($1.20) earnings per share for the quarter, beating the consensus estimate of ($1.38) by $0.18. REGENXBIO had a negative return on equity of 78.29% and a negative net margin of 110.29%.The company had revenue of $29.73 million during the quarter, compared to the consensus estimate of $24.41 million. As a group, equities analysts predict that REGENXBIO will post -4.84 EPS for the current year.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.